AzTrials
AzTrials

Pregnancy RelatedEarly Phase 1uSI-rangesNCT04548453

Establish the uSI Values and End-user Training Material That Will be Used to Guide Oxytocin Dosing Actions

A Early Phase 1 study testing uterine electromyography in people with Pregnancy Related and Labor Long, run by PreTeL, Inc at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Patients receiving oxytocin for induction or augmentation of labor will be studied with uterine EMG. The results of the EMG will be converted to an oxytocin-associated uterine stimulation index (uSI), which is intended to guide decisions for changing the dose of oxytocin. Read more about this study

Who is it for?
Ages 18 to 50 years, women onlyHealthy volunteers can take part
Conditions the study is for
Pregnancy Related, Labor Long, Fetal Distress
What is being tested?
uterine electromyography
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
51 participants
Where
1 siteUnited States
Study dates
Apr 2021to Oct 2021
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age 18 or greater
  • At least 37 weeks gestation
  • English reading and speaking
  • Female gender
  • Singleton fetus
  • Planned continuous external fetal monitoring: to include fetal heart rate and uterine contraction monitoring
Show all 14Show fewer
  • May have clinical indications for internal monitoring (IUPC and/or FSE) that replaces external monitoring.
  • Induction or augmentation of labor with oxytocin (Pitocin)
  • Subjects undergoing artificial rupture of membranes (AROM) or who experienced spontaneous rupture of membranes (SROM), with a plan for oxytocin administration, will be included as a special category.
  • Subjects may undergo cervical ripening.
  • Patients must be able to review and sign informed consent to participate in the study.
  • Trial of labor after Cesarean section are eligible for participation
  • Women diagnosed with diabetes and/or pre-eclampsia with or without magnesium therapy are eligible for participation
  • Women with other complications of pregnancy are eligible for participation if the complication does not interfere with fetal monitoring, EMG monitoring or other recording of data.

Who cannot join

  • Non-English reading and/or speaking
  • Twins, triplets and other multifetal gestations
  • Non-vertex presentation
  • Planned Cesarean delivery
  • Significant uterine anomalies such as didelphys or bicornuate uterus (women with small, clinically insignificant anomalies such as uterine fibroids are not excluded).
  • Participants cannot be participating in any other research study or protocol regarding uterine contraction monitoring during the same study period as required for our study.
Show all 11Show fewer
  • Known allergy to ECG pad adhesive
  • Non-living fetus
  • Major fetal malformation
  • Fetal distress, or other indications for emergent delivery
  • Other than a Category I fetal heart tracing at the beginning of the recording.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Rochester

    Rochester, New York, 14642

Other trials in United States

About this study

Patients receiving oxytocin for induction or augmentation of labor will be studied with uterine EMG. The results of the EMG will be converted to an oxytocin-associated uterine stimulation index (uSI), which is intended to guide decisions for changing the dose of oxytocin. An expert panel will review the results of the oxytocin dosing actions, then assigned optimized actions throughout the labor. The uSI will be correlated with the optimal dosing actions.

Read the detailed description

Background. Oxytocin stimulates the uterus, increases the strength and frequency of uterine contractions and facilitates delivery. The "dose" of oxytocin is the rate of IV infusion. In a typical labor where oxytocin is used, many dosing adjustments are performed over many hours. Finding the correct dose for a given patient is challenging because some women respond rapidly to low doses of oxytocin, others require high doses. The correct dose is important because the risks of adverse outcomes increase when doses are either too low or excessive. The dosing actions increase, hold, decrease or stop are typically performed every 30 minutes during oxytocin administration.

Dosing actions are performed based on the current level of simulation caused by the current dose. To assess the level of stimulation, current methods rely heavily on the output of the fetal monitor, which produces contraction frequency and fetal heart rate. Additional information for dosing decisions is obtained from subjective assessments such uterine palpation. Subjective measures are used because there is no objective method available to reliably guide a dosing action. Subjectivity is a major contributor to the long duration of labor for inductions and the high rate of excessive uterine stimulation with any oxytocin use.

The uterine stimulation index (uSI) is an objective measure of the current level of stimulation caused by the current dose of oxytocin in individual patients and can be used to guide oxytocin dosing actions. uSI is based on an electromyography (EMG) signal that is proportional to the effects of oxytocin on the uterine muscle. uSI is calculated from multichannel EMG to obtain a representative sampling of the effects of oxytocin on entire uterus. The range of values for uSI is from 0 (no oxytocin effects) to 10 (maximal oxytocin effects). Low values of uSI guide the end-user to increase the current dose of oxytocin. Intermediate values of uSI guide the end-user to hold the current dose. High values of uSI guide the end-user to decrease the current dose.

The purpose of this study is to establish the ranges of uSI values that correspond to the dosing actions increase, hold and decrease. To establish these ranges, 51 subjects will undergo current methods of dosing while having multichannel EMG recorded. uSI values will not be available to end-users, so all subjects will receive dosing actions determined by standard of care using current method. After delivery, a panel of experts will retrospectively assess each dosing action based on the outcome of the dosing action. These "optimized dosing actions" will then be correlated with the uSI value obtained at that time. This process produces paired data of optimized actions and uSI values. From the clustering of the uSI values, the ranges of uSI can be matched to the dosing actions increase, hold and decrease.

As a second goal, human factors will be studied with questionnaires and end-user interviews to improve the methods used for recording multichannel EMG during labor.

Procedure. Patients receiving oxytocin for clinical indications will be approached for participation. After obtaining consent, up to 8 proprietary EMG sensors will be placed over the subject's abdomen, spanning most of the surface of the uterus. Additionally, one ground sensor and one noise rejection sensor will be placed. Multichannel EMG recordings will be obtained throughout the labor, although the results of the EMG will not be available to the obstetrical providers. Subjects will be managed using current methods of monitoring and standard of care for oxytocin dosing decisions.

At the conclusion of the recording, the EMG sensors will be removed from the subject. Data will be analyzed after delivery, producing uSI values as a function of time for the duration of the labor.

An expert panel will be assembled, composed of clinicians trained in the art of obstetrics and managing oxytocin. The progress of labor will be assessed by examining the fetal monitor strip (i.e. uterine contractile activity and the fetal heart rate over time), cervical changes, and the dosing actions performed. No less than 72 hours after delivery the neonate's and subject's medical records will be reviewed to identify complications of the delivery that may have occurred.

The expert panel will assess each dosing action as optimal or not optimal. An example of a not optimal action would be increasing the dose and causing uterine tachysytole. In this example, "hold" will be assigned as the optimized dosing action. Each subject will have a list of optimized dosing actions and the time they were performed. Optimized dosing actions will then be linked with uSI values observed at that time, creating a paired data set of uSI values and optimal dosing actions.

The optimized dosing actions increase, hold and decrease will be correlated with uSI values and the range of uSI values that correspond with each dosing action will be established.

End-users will be interviewed 1 to 72 hours after delivery of the baby. The interview will identify barriers to EMG recording may influence the effectiveness of the information provided by the multichannel EMG recording.

Being tested
uterine electromyography
Keywords
labor, oxytocin, tachysystole, prolonged labor
Medical subject headings
Fetal Distress

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • uterine electromyographyDevice

    Also called electrohysterography

    Multichannel uterine electromyography will record uterine biosignals during labor.

Study groups in NCT04548453
Study groupRoleWhat they receive
Uterine EMG during laborExperimentalMultichannel uterine electromyography will be recorded on patients receiving oxytocin for induction or augmenation of labor.
Receives: Device: uterine electromyography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlating uSI with the optimized dosing actions increase, hold and decrease

    uSI clustering with dosing actions will be identified to provide guidance when prospectively dosing oxytocin

    Measured: 8 months

  2. Human factors in recording multichannel EMG during labor

    Difficulties and discomfort of the EMG recording process will be identified and corrected

    Measured: 8 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Sep 2020
  2. Study startApr 2021 (estimated)
  3. Primary completionOct 2021 (estimated)
  4. Study completionOct 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
prospective, non-significant risk
Masking
None (open label)
Enrolment
51 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04548453
Sponsor's protocol ID
uSI range setting study
Acronym
uSI-ranges
Status last verified
Sep 2020
First submitted
1 Sep 2020
Last updated
14 Sep 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: No IPD will be shared with other researchers. Data in summary form, based on numerical assessments of the uSI and optimized dosing actions will be published.

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing uterine electromyography in people with Pregnancy Related and Labor Long, run by PreTeL, Inc at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Roger C Young, MD (16033598870, ryoung@pretelhealth.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlating uSI with the optimized dosing actions increase, hold and decrease (time frame: 8 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in